Furiex Pharmaceuticals
Morrisville
About Furiex Pharmaceuticals
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 10,001+
- Estimated revenue: $10K – $50K
- Total funding: $15.0M
- Funding stage: M&A
- Last round: Post-IPO Debt (Oct 2013)
- Ticker: nasdaq:FURX
- Website: furiex.com
- Phone: +119194567850
Industries & Categories
Biotechnology, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/furiex-pharmaceuticals-2174877 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.